Functional in vitro assessment of the HER2 Ile655Val variant on trastuzumab-induced cardiotoxicity in human cardiomyocytes
European Journal of Pharmacology · 2026
DOI: 10.1016/j.ejphar.2025.178484 ↗Kurz gefasst
Fachartikel in der Zeitschrift European Journal of Pharmacology, 2026. Verfasst von Ana Pozo-Agundo und 13 weiteren Autor:innen. Beteiligte Einrichtung: GENYO: Center for Genomics and Oncological Research: Pfizer-University of Granada-Junta de Andalucía, Granada, Spain. Electronic address: b22poaga@co…. Hauptthemen laut MEDLINE: Trastuzumab, Myocytes, Cardiac, Erb-b2 Receptor Tyrosine Kinases, Cardiotoxicity. Die Arbeit nennt 32 Literaturangaben. Gefördert von: Instituto de Salud Carlos III, Ministerio de Ciencia, Innovación y Universidades.
Abstract (Originalsprache)
AIMS: Treatment of HER2 positive (HER2+) breast cancer has significantly improved since the development of trastuzumab. However, approximately 30 % of patients develop trastuzumab-induced cardiotoxicity (TIC) manifested as a decrease in left ventricular ejection fraction (LVEF), with nearly 5 % of cases progressing to congestive heart failure. While TIC is generally reversible upon treatment discontinuation, the underlying mechanisms of this adverse reaction remain incompletely understood. Emerging evidence suggests that genetic factors may contribute to individual susceptibility. The variant rs1136201 in the ERBB2 gene, also known as HER2 Ile655Val or I655V, has been studied for its association with TIC, yet its role remains controversial. This study investigates the implication of the rs1136201 variant in cardiotoxicity in in vitro models of human cardiomyocytes exposed to trastuzumab. METHODS AND RESULTS: We generated AC16 ventricular cardiomyocyte cell models representing the three genotypes of the rs1136201 variant and performed transcriptomic analysis following trastuzumab exposure. Furthermore, we established a second model consisting of human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) from patients carrying the rs1136201 variant and controls and evaluated the impact of this variant on mitochondrial function and contractility after trastuzumab treatment. Transcriptomic analysis revealed alteration of the electron transport chain, ATP synthesis, cellular respiration, and ribosome biogenesis in cells carrying the rs1136201 variant after trastuzumab exposure. hiPSC-CMs showed a reduction in upstroke (p = 0.0107) and downstroke velocities (p = 0.0117) compared to controls. CONCLUSION: Our preliminary findings support the potential role of rs1136201 in TIC and underscore the need for further studies.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- GENYO: Center for Genomics and Oncological Research: Pfizer-University of Granada-Junta de Andalucía, Granada, Spain. Electronic address: b22poaga@correo.ugr.es.
- GENYO: Center for Genomics and Oncological Research: Pfizer-University of Granada-Junta de Andalucía, Granada, Spain. Electronic address: garciarodriguez.sonia@gmail.com.
- GENYO: Center for Genomics and Oncological Research: Pfizer-University of Granada-Junta de Andalucía, Granada, Spain. Electronic address: albantunez@gmail.com.
- Department of Biochemistry and Molecular Biology III and Immunology, Faculty of Medicine, University of Granada, Granada, Spain. Electronic address: luciachica@ugr.es.
- Department of Pharmacology, Northwestern University Feinberg School of Medicine, Chicago, IL, USA; Center for Pharmacogenomics, Northwestern University Feinberg School of Medicine, Chicago, IL, USA. Electronic address:…
- GENYO: Center for Genomics and Oncological Research: Pfizer-University of Granada-Junta de Andalucía, Granada, Spain; Department of Biochemistry and Molecular Biology III and Immunology, Faculty of Medicine, University…
Förderung
- Instituto de Salud Carlos III
- Ministerio de Ciencia, Innovación y Universidades
Zitieren
APA
Pozo-Agundo, A., García-Rodríguez, S., Antúnez-Rodríguez, A., Chica-Redecillas, L., Cejas, R. B., Lyra-Leite, D., Porras-Quesada, P., Gómez-Sánchez, J., Mirón-Pozo, B., Álvarez-Cubero, M. J., Burridge, P. W., Martin, F., Martínez-González, L. J., & Dávila-Fajardo, C. L. (2026). Functional in vitro assessment of the HER2 Ile655Val variant on trastuzumab-induced cardiotoxicity in human cardiomyocytes. European Journal of Pharmacology. https://doi.org/10.1016/j.ejphar.2025.178484
Vancouver
Pozo-Agundo A, García-Rodríguez S, Antúnez-Rodríguez A, Chica-Redecillas L, Cejas RB, Lyra-Leite D, et al. Functional in vitro assessment of the HER2 Ile655Val variant on trastuzumab-induced cardiotoxicity in human cardiomyocytes. European Journal of Pharmacology. 2026. doi:10.1016/j.ejphar.2025.178484
BibTeX
@article{PozoAgundo2026,
author = {Pozo-Agundo, Ana and García-Rodríguez, Sonia and Antúnez-Rodríguez, Alba and Chica-Redecillas, Lucía and Cejas, Romina Beatriz and Lyra-Leite, Davi and Porras-Quesada, Patricia and Gómez-Sánchez, Javier and Mirón-Pozo, Benito and Álvarez-Cubero, María Jesús and Burridge, Paul W and Martin, Francisco and Martínez-González, Luis Javier and Dávila-Fajardo, Cristina Lucía},
title = {Functional in vitro assessment of the HER2 Ile655Val variant on trastuzumab-induced cardiotoxicity in human cardiomyocytes},
journal = {European Journal of Pharmacology},
year = {2026},
doi = {10.1016/j.ejphar.2025.178484}
}
EUVIMED